Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AXSM

AXSM - Axsome Therapeutics Inc Stock Price, Fair Value and News

84.84USD+2.70 (+3.29%)Market Closed

Market Summary

AXSM
USD84.84+2.70
Market Closed
3.29%

AXSM Stock Price

View Fullscreen

AXSM RSI Chart

AXSM Valuation

Market Cap

4.0B

Price/Earnings (Trailing)

-13.6

Price/Sales (Trailing)

16.05

EV/EBITDA

-13.89

Price/Free Cashflow

-20.84

AXSM Price/Sales (Trailing)

AXSM Profitability

EBT Margin

-118.71%

Return on Equity

-205.77%

Return on Assets

-54.31%

Free Cashflow Yield

-4.8%

AXSM Fundamentals

AXSM Revenue

Revenue (TTM)

251.0M

Rev. Growth (Yr)

-20.7%

Rev. Growth (Qtr)

4.85%

AXSM Earnings

Earnings (TTM)

-296.4M

Earnings Growth (Yr)

-509.35%

Earnings Growth (Qtr)

30.71%

Breaking Down AXSM Revenue

Last 7 days

2.4%

Last 30 days

11.6%

Last 90 days

25.0%

Trailing 12 Months

14.0%

How does AXSM drawdown profile look like?

AXSM Financial Health

Current Ratio

3.2

Debt/Equity

1.24

Debt/Cashflow

-1.08

AXSM Investor Care

Shares Dilution (1Y)

9.00%

Diluted EPS (TTM)

-6.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024251.0M000
2023144.6M182.5M223.4M270.6M
202200050.0M
20210000
20200000
201900287.1K356.9K
2018209.7K212.3K214.8K217.4K
2017000207.1K
20161.8M1.4M914.0K474.3K
20140002.2M

Tracking the Latest Insider Buys and Sells of Axsome Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 29, 2024
jacobson mark l.
acquired
17,800
1.3
13,693
chief operating officer
May 29, 2024
jacobson mark l.
sold
-587,813
74.3127
-7,910
chief operating officer
May 29, 2024
coleman mark
sold
-394,333
75.1396
-5,248
-
May 28, 2024
coleman mark
sold
-394,775
75.2095
-5,249
-
Apr 01, 2024
jacobson mark l.
acquired
32,060
1.3
24,662
chief operating officer
Apr 01, 2024
jacobson mark l.
sold
-1,904,940
77.242
-24,662
chief operating officer
Mar 15, 2024
jeffs roger
sold
-168,062
71.6072
-2,347
-
Mar 15, 2024
jeffs roger
acquired
70,198
29.91
2,347
-
Mar 14, 2024
jeffs roger
sold
-2,089,390
69.702
-29,976
-
Mar 14, 2024
jeffs roger
acquired
719,787
24.0121
29,976
-

1–10 of 35

Which funds bought or sold AXSM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
4.12
3,802
79,373
-%
Jul 19, 2024
First Horizon Advisors, Inc.
unchanged
-
12.00
1,288
-%
Jul 19, 2024
Hennion & Walsh Asset Management, Inc.
reduced
-6.91
-337,601
5,207,140
0.27%
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
reduced
-2.11
-8,792
695,762
-%
Jul 19, 2024
MONECO Advisors, LLC
unchanged
-
5,240
602,543
0.09%
Jul 19, 2024
China Universal Asset Management Co., Ltd.
reduced
-38.7
-277,229
449,190
0.06%
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
reduced
-9.78
-124,242
1,257,970
-%
Jul 18, 2024
VALLEY NATIONAL ADVISERS INC
unchanged
-
-
1,000
-%
Jul 18, 2024
Assenagon Asset Management S.A.
new
-
2,734,500
2,734,500
0.01%
Jul 18, 2024
Blue Trust, Inc.
new
-
3,830
3,830
-%

1–10 of 48

Are Funds Buying or Selling AXSM?

Are funds buying AXSM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AXSM
No. of Funds

Unveiling Axsome Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
fairmount funds management llc
4.9%
2,360,077
SC 13G/A
Feb 14, 2024
rtw investments, lp
9.5%
4,489,596
SC 13G/A
Feb 13, 2024
vanguard group inc
7.81%
3,696,766
SC 13G/A
Jan 26, 2024
blackrock inc.
6.8%
3,239,746
SC 13G/A
Jul 07, 2023
fairmount funds management llc
5.0%
2,344,980
SC 13G
Feb 14, 2023
venrock healthcare capital partners ii, l.p.
0.0%
0
SC 13G/A
Feb 14, 2023
fairmount funds management llc
4.6%
2,011,647
SC 13G/A
Feb 14, 2023
rtw investments, lp
6.9%
2,980,482
SC 13G
Feb 14, 2023
pfm health sciences, lp
3.2%
6
SC 13G/A
Feb 09, 2023
vanguard group inc
7.87%
3,417,628
SC 13G/A

Recent SEC filings of Axsome Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
8-K
Current Report
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 05, 2024
8-K
Current Report
May 29, 2024
4
Insider Trading
May 29, 2024
4
Insider Trading
May 29, 2024
144
Notice of Insider Sale Intent
May 29, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Axsome Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Axsome Therapeutics Inc News

Latest updates
MarketBeat20 hours ago
The Motley Fool11 Jun 202407:00 am
Investor's Business Daily5 months ago

Axsome Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q12019Q42019Q32018Q42018Q32018Q22018Q1
Revenue4.8%74,999,00071,530,00057,794,00046,700,00094,576,00024,371,00016,846,0008,820,000--------139,448-217,418270,325323,232
Costs and Expenses-16.2%142,274,000169,804,000119,914,000111,757,000100,950,00084,288,50059,258,00048,001,00038,289,00032,608,11033,407,14230,847,687---------
Operating Expenses---------38,288,87232,608,04033,407,14230,847,68727,844,06127,744,23632,491,45724,428,17018,947,2359,450,3158,243,4597,989,5937,163,210
  S&GA Expenses14.0%98,970,00086,809,00083,188,00078,935,00074,191,00061,498,00040,892,00031,160,00025,704,00018,826,38320,226,88416,344,36111,248,37210,359,5074,970,0575,222,8993,111,6622,299,0832,202,6792,439,061-
  R&D Expenses19.6%36,830,00030,803,00028,767,00020,581,00017,793,00014,693,00014,877,00015,792,00012,585,00013,781,72813,180,25814,503,32616,595,68917,384,72927,521,40019,205,27115,835,5737,151,2326,040,7805,550,532-
EBITDA Margin-36.1%-1.11-0.82-0.83-0.93-1.01-3.58-347-351-352-352-----------
Interest Expenses0.7%4,903,0004,868,0004,730,0003,916,0003,216,0002,569,0002,531,0001,467,0001,119,0001,142,9171,169,1661,169,1671,143,750917,955379,167308,339383,334186,941182,357195,801-
Income Taxes100.0%--325,000-678,000-617,0002,580,000--------------217,418--
Earnings Before Taxes30.9%-68,357,000-98,976,000-62,877,000-67,787,000-8,638,000-61,241,000-44,823,000-41,438,000-39,632,000------------
EBT Margin-34.8%-1.19-0.88-0.90-1.00-1.08-3.74-365-365-365-365-----------
Net Income30.7%-68,357,000-98,651,000-62,199,000-67,170,000-11,218,000-61,240,500-44,823,000-41,439,000-39,632,000-33,976,144-34,882,677-32,284,209-29,259,970-29,164,647-32,484,146-24,806,984-19,135,612-9,597,015-8,281,974-8,280,916-
Net Income Margin-33.5%-1.18-0.88-0.90-1.01-1.10-3.74-447-420-394-365-351-318---------
Free Cashflow-76.4%-53,565,000-30,369,000-53,919,000-55,482,000-5,892,000-27,744,000-22,824,000-33,778,000-32,867,000-28,841,206-27,034,880-25,412,430---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.2%54658860161238933133918189.0088.0011714316718620419119822144.0055.0044.00
  Current Assets-8.7%46050451252030424625210487.0087.0011514216518420319119822044.0055.0044.00
    Cash Equivalents-14.2%33138641743724720122873.0085.0086.0011514116518420219119722044.0054.0043.00
  Inventory3.0%16.0015.0010.009.008.004.002.0010.00-------------
  Net PPE-4.0%1.001.001.001.001.001.001.001.000.000.000.000.000.000.000.000.000.000.000.000.000.00
  Goodwill-0.3%12.0012.0012.0012.0010.0010.0012.0012.0012.00------------
Liabilities1.1%40239733133327722218216574.0072.0074.0072.0071.0072.0068.0037.0042.0042.0038.0030.0027.00
  Current Liabilities3.7%14413911511510197.0060.0043.0025.0023.0025.0023.0022.0023.0020.0023.0026.0024.0019.0013.008.00
  Long Term Debt0.3%17917817717714894.0094.0093.0049.0049.0049.0049.0049.0048.0048.0014.0016.0017.0019.0017.0019.00
    LT Debt, Current----------------7.005.003.001.002.001.00
    LT Debt, Non Current0.3%17917817717714894.0094.0093.0049.0049.0049.0049.0049.0048.0048.0014.0016.0017.0019.0017.0019.00
Shareholder's Equity-24.6%14419127027911211015715.0015.0016.0043.0071.0096.001141351541561797.0024.0017.00
  Retained Earnings-8.2%-903-835-736-674-607-596-535-490-448-409-375-340-308-278-249-226-208-175-151-132-118
  Additional Paid-In Capital2.1%1,0481,0271,006954719706692505464425418412404393385381365355158156136
Shares Outstanding0.2%47.0047.0047.0047.0044.0043.0042.0039.0038.0038.0038.0038.00---------
Float----2,800---1,200---2,000---2,400---675-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-76.1%-53,467-30,362-53,548-55,349-5,821-27,563-22,758-33,537-32,653-28,840-26,776-25,393-27,215-20,553-15,734-18,895-23,273-17,567-10,626-8,681-9,499
  Share Based Compensation6.7%20,19018,91514,84015,92212,94310,7689,19810,1627,5985,8905,7255,4563,7315,6062,8694,1482,1342,8141,1568891,256
Cashflow From Investing-1300.0%-98.00-7.00-371-133-71.00-181-66.00-53,241-214-451*-258-18.88-29.99-20.29-14.84-1.43-9.33-1.46-3.20--
Cashflow From Financing-59250.0%-1,187-2.0033,370246,08051,5651,066176,95075,46431,1026914391,9718,0292,09027,42812,265630193,89351919,82238,155
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AXSM Income Statement

2024-03-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues [Abstract]  
Revenue$ 74,999$ 94,576
Operating expenses:  
Cost of revenue (excluding amortization and depreciation)6,2977,556
Research and development36,83017,793
Selling, general and administrative98,97074,191
Gain in fair value of contingent consideration(1,412)(162)
Intangible asset amortization1,5891,572
Total operating expenses142,274100,950
Loss from operations(67,275)(6,374)
Interest expense, net(1,082)(2,264)
Loss before income taxes(68,357)(8,638)
Income tax expense0(2,580)
Net loss$ (68,357)$ (11,218)
Net loss per common share, basic$ (1.44)$ (0.26)
Net loss per common share, diluted$ (1.44)$ (0.26)
Weighted average common shares outstanding, basic47,393,56343,523,631
Weighted average common shares outstanding, diluted47,393,56343,523,631
Product Sales  
Revenues [Abstract]  
Revenue$ 74,096$ 28,569
License Revenue  
Revenues [Abstract]  
Revenue 65,735
Royalty Revenue  
Revenues [Abstract]  
Revenue$ 903$ 272

AXSM Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 331,441$ 386,193
Accounts receivables, net101,43494,820
Inventories, net15,58315,135
Prepaid and other current assets12,0328,115
Total current assets460,490504,263
Equipment, net812846
Right-of-use asset - operating lease6,4116,772
Goodwill12,04212,042
Intangible asset, net51,69753,286
Non-current inventory and other assets14,27611,027
Total assets545,728588,236
Current liabilities:  
Accounts payable53,79140,679
Accrued expenses and other current liabilities82,71690,501
Operating lease liability, current portion1,1531,267
Contingent consideration, current6,3886,407
Total current liabilities144,048138,854
Contingent consideration, non-current70,00073,300
Loan payable, long-term178,689178,070
Operating lease liability, long-term7,2587,035
Finance lease liability, long-term1,697 
Total liabilities401,692397,259
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding)
Common stock, $0.0001 par value per share (150,000,000 shares authorized, 47,464,575 and 47,351,363 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively)55
Additional paid-in capital1,047,9591,026,543
Accumulated deficit(903,928)(835,571)
Total stockholders’ equity144,036190,977
Total liabilities and stockholders’ equity$ 545,728$ 588,236
AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
 CEO
 WEBSITEaxsome.com
 INDUSTRYBiotechnology
 EMPLOYEES422

Axsome Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Axsome Therapeutics Inc? What does AXSM stand for in stocks?

AXSM is the stock ticker symbol of Axsome Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axsome Therapeutics Inc (AXSM)?

As of Fri Jul 19 2024, market cap of Axsome Therapeutics Inc is 4.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXSM stock?

You can check AXSM's fair value in chart for subscribers.

What is the fair value of AXSM stock?

You can check AXSM's fair value in chart for subscribers. The fair value of Axsome Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axsome Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXSM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axsome Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AXSM is over valued or under valued. Whether Axsome Therapeutics Inc is cheap or expensive depends on the assumptions which impact Axsome Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXSM.

What is Axsome Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, AXSM's PE ratio (Price to Earnings) is -13.6 and Price to Sales (PS) ratio is 16.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXSM PE ratio will change depending on the future growth rate expectations of investors.